Screener
PSP vs PBE
Invesco Global Listed Private Equity ETF vs Invesco Biotechnology & Genome ETF
Key differences
- PBE costs 1.22% less per year.
- Over the last 3 years, PSP has delivered higher annualized returns.
Side-by-side comparison
| PSP | PBE | |
|---|---|---|
| Annual cost (TER) | 1.80% | 0.58% |
| Fund size (AUM) | $255M | $247M |
| Since | 2006 | 2005 |
| Dividend yield | 6.36% | 1.09% |
| Asset class | equity | equity |
| Region | — | north america |
| Strategy | index tracking | index tracking |
| CAGR 1Y | -1.5% | +35.8% |
| CAGR 3Y | +12.9% | +10.3% |
| CAGR 5Y | +1.2% | +3.5% |
| Sharpe 3Y | 0.52 | 0.41 |
| Volatility 1Y | 19.45% | 18.63% |
| Max drawdown | -47.17% | -37.84% |
Green dot indicates the better value for that metric. Performance data is historical and does not predict future results.
Similar to PSP and PBE
Explore further